Clinical trial · Interventional
Progressive Muscle Relaxation Delivered Via Virtual Reality - an Intervention for Patients Undergoing Cellular Therapy
PMR Delivered Via VR - a Cellular Therapy Intervention
NCT07649512CI-TRIAL-00114951not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients planned for cellular therapy supplementation such as CAR-T or stem cell transplant who are admitted for atleast 7 days in patient. During that time of admission, patients enrolled will complete a once daily, virtual reality guided progressive muscle relaxation program. Various validated QOL tools will be utilized to assess study results.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Heme Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Progressive Muscle Relaxation delivered via Virtual Reality | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention arm - single arm feasibility study
- description
- Patients will undergo intervention (PMR delivered via VR). All patients will undergo the intervention.
- interventionNames
- Combination Product: Progressive Muscle Relaxation delivered via Virtual Reality
Primary outcomes (1)
- measure
- Recruitment, Retention, and Adherence Rates of VR-Guided Progressive Muscle Relaxation (PMR) Intervention
- timeFrame
- Enrollment through completion of the 7-day intervention period.
- description
- Feasibility will be assessed using three operational metrics: Recruitment rate - the proportion of eligible patients who consent to participate in the study. Retention rate - the proportion of enrolled participants who complete the 7-day intervention period. Adherence rate - the proportion of participants who complete at least 5 VR-guided PMR sessions lasting up to 20 minutes each during the first 7 days of hospitalization. These outcomes will be summarized descriptively as proportions and percentages among enrolled participants.
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Able to provide informed consent 2. Age greater than or equal to 18 years old 3. Either have a planned admission or already be admitted to the in-patient oncology ward (3NW) with cellular therapy needs. 4. Able to understand English 5. Able to sit-up in bed or bedside chair space to utilize VR device at the time of enrollment 6. Able to utilize VR device and computer/laptop to access necessary resources for participation 7. Performance Status as defined by European Cooperative Oncology Group (ECOG) score of 0-2 Exclusion Criteria: 1. Poor performance status of ECOG 3-4 2. Recent use of immersive VR programs for stress relief and/or entertainment (more than 2 days/week within the past 3 months) 3. Participation in another stress-reduction type interventional study within the past 3 months 4. Current or history of seizure, epilepsy, or other known severe neurological or mental health disorders 5. Clinical Sensitivity to flashing light or motion or having balance disorders previously diagnosed 6. Having another medical condition or co-morbidity that may prevent use of VR program or physical materials (e.g., visual or hearing problems, open sores, wounds, skin rash on face, or active infection) 7. Patients with concern for neurotoxicity or acute treatment related neurological issues such as ICANS. ICANS grade 1 maybe eligible to re-enter trial. ICANS grade 2 or greater would be permanently excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.